HRP20100560T1 - Minimalna dnk sekvenca koja djeluje kao izolator kromatina i njena upotreba u ekspresiji proteina - Google Patents
Minimalna dnk sekvenca koja djeluje kao izolator kromatina i njena upotreba u ekspresiji proteina Download PDFInfo
- Publication number
- HRP20100560T1 HRP20100560T1 HR20100560T HRP20100560T HRP20100560T1 HR P20100560 T1 HRP20100560 T1 HR P20100560T1 HR 20100560 T HR20100560 T HR 20100560T HR P20100560 T HRP20100560 T HR P20100560T HR P20100560 T1 HRP20100560 T1 HR P20100560T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- interest
- polypeptide
- human
- subunit
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract 7
- 108010077544 Chromatin Proteins 0.000 title claims abstract 3
- 210000003483 chromatin Anatomy 0.000 title claims abstract 3
- 239000012212 insulator Substances 0.000 title claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims 5
- 108090000623 proteins and genes Proteins 0.000 title claims 5
- 102000004169 proteins and genes Human genes 0.000 title claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract 6
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 intron Proteins 0.000 claims 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 claims 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims 2
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000048120 Galactokinases Human genes 0.000 claims 1
- 108700023157 Galactokinases Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 101710205006 Interleukin-18-binding protein Proteins 0.000 claims 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 claims 1
- 108010025815 Kanamycin Kinase Proteins 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 206010048723 Multiple-drug resistance Diseases 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 claims 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- 238000003153 stable transfection Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Upotreba vektora koji sadrži jedan ili više izolatora kromatina naznačena time da sadrži SEQ ID NO: 1 za ekspresiju gena od interesa u CHO stanici. Patent sadrži još 23 patentna zahtjeva.
Claims (24)
1. Upotreba vektora koji sadrži jedan ili više izolatora kromatina naznačena time da sadrži SEQ ID NO: 1 za ekspresiju gena od interesa u CHO stanici.
2. Upotreba prema zahtjevu 1, naznačena time da navedeni vektor nadalje sadrži barem jedan DNA element odabran od:
a. pojačivača ili funkcionalne ekspresije za poboljšavanje njegovih fragmenata
b. promotorske domene ili funkcionalne ekspresije za promociju njegovih fragmenata; i
c. DNA sekvence kodiranja za jedan ili više polipeptida od interesa.
3. Upotreba prema zahtjevu 1 ili 2, naznačena time da navedeni vektor nadalje sadrži jednu ili više DNA sekvenci kodiranja za regulatorne elemente koji se biraju iz 5'UTR, introna, 3'UTR, mRNA 3' završne obrade sekvence, poliadenilacijskog mjesta, i unutarnjih ribosomskih ulaznih sekvenci (IRES).
4. Upotreba prema zahtjevu 2 ili 3, naznačena time da DNA sekvenca kodira više od jednog polipeptida od interesa kroz policistroničku mRNA.
5. Upotreba prema bilo kojem od zahtjeva 1 do 4, naznačena time da navedeni vektor nadalje sadrži jedan ili više DNA elemenata odabranih od graničnih elemenata, lokus kontrolnih područja (LCR), matričnih vezanih regija (MAR), i elemenata za rekombinaciju i kasetnu izmjenu.
6. Upotreba prema bilo kojem od zahtjeva 1 do 5, naznačena time da promotor je odabran od staničnih ili viralnih/fag promotora kao što su mCMV-IE1, mCMV-IE2, hCMV, SV40, RSV, T7, T3, ili funkcionalne ekspresije za promociju njegovog fragmenta.
7. Upotreba prema bilo kojem od zahtjeva 1 do 6, naznačena time da je polipeptid od interesa odabran od FSH, LH, CG, TSH, hormona rasta, interferona, TNF vezujućeg proteina I, TNF vezujućeg proteina II, IL-18BP, IL-6, IFNAR1, LIF ili muteina, fragmenata, funkcionalnih derivata, te njegovih fuzijskih proteina.
8. Upotreba prema bilo kojem od zahtjeva 1 do 6. naznačena time da je polipeptid od interesa odabran od EPO, G-CSF, GM-CSF, lanca humaniziranih antitijela, citokina, koagulacijskog faktora, etanercepta, tPA, integrina ili muteina, fragmenata, funkcionalnih derivata, te njegovih fuzijskih proteina.
9. Upotreba prema bilo kojem od zahtjeva 1 do 6 naznačena time da je polipeptid od interesa odabran od adenozin deaminaze (ADA), aminoglikozidne fosfotransferaze (neo), dihidrofolatne reduktaze (DHFn), higromicin-B-fosfotransferaze (HPH), timidin kinaze (tk) , ksantin-gvanin fosforiboziltransferaze (gpt), multiplog gena otpornog na lijek (MOR), ornitin dekarboksilaze (ODC) i rezistentne N-(fosfonacetil)-L-aspartaze (CAD), puromicin aktiltransferaze (PAC), galaktokinaze, humanog folatnog receptora, ili reduciranih folatnih nosača.
10. Upotreba prema bilo kojem od zahtjeva 1 do 6, naznačena time da je polipeptid od interesa odabran od luciferaze, zelenog fluorescentnog proteina, alkalne fosfataze i hren peroksidaze ili njihovih kombinacija.
11. Upotreba prema bilo kojem od zahtjeva 1 do 10, naznačena time da jedan izolator je smješten uzvodno i jedan izolator je smješten nizvodno od DNA koja kodira polipeptid od interesa.
12. Upotreba prema bilo kojem od zahtjeva 1 do 10, naznačena time da su barem dva izolatora smještena uzvodno i nizvodno od DNA sekvence koja kodira odgovarajući polipeptid od interesa.
13. Upotreba prema bilo kojem od zahtjeva 11 ili 12, naznačena time da su barem dvije kodirajuće sekvence smještene između izolatora.
14. Upotreba prema zahtjevu 13, naznačena time da barem dvije kodirajuće sekvence kodiraju podjedinice multimernog proteina.
15. Upotreba prema zahtjevu 14, naznačena time da prva podjedinica je alfa lanac i druga podjedinica je beta lanac hormona odabranog od humanog FSH, humanog LH humanog TSH i humanog CG.
16. Upotreba prema zahtjevu 14, naznačena time da prva podjedinica je beta lanac i druga podjedinica je alfa lanac hormona odabranog od humanog FSH, humanog LH, humanog TSH i humanog CG.
17. Upotreba prema zahtjevu 14, naznačena time da prva podjedinica je teški lanac i druga podjedinica je lagani lanac imunoglobulina.
18. Upotreba prema zahtjevu 14, naznačena time da prva podjedinica je lagani lanac i druga podjedinica je teški lanac imunoglobulina.
19. Upotreba prema bilo kojem od zahtjeva 1 do 18 naznačena time da je za istovremenu ekspresiju dva ili više gena ili DNA od interesa.
20. CHO stanica naznačena time da je transfekcirana sa vektorom kako je definirano u bilo kojem od zahtjeva 1 do 19.
21. Postupak za dobivanje polipeptida od interesa naznačen time da sadrži korak transfekcije CHO stanice sa barem jednim vektorom kako je definirano u bilo kojem od zahtjeva 1 do 18.
22. Postupak za dobivanje polipeptida od interesa naznačen time da sadrži korak uzgoja CHO stanica prema zahtjevu 20.
23. Postupak prema zahtjevu 21 ili 22, naznačen time da nadalje sadrži korak izolacije polipeptida od interesa iz CHO stanica.
24. Postupak prema bilo kojem od zahtjeva 21 do 23, naznačen time da transfekcija je stabilna transfekcija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03103890 | 2003-10-21 | ||
| PCT/EP2004/052591 WO2005040384A1 (en) | 2003-10-21 | 2004-10-20 | Minimal dna sequence acting as a chromatin insulator and its use in protein expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100560T1 true HRP20100560T1 (hr) | 2010-11-30 |
Family
ID=34486337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100560T HRP20100560T1 (hr) | 2003-10-21 | 2010-10-14 | Minimalna dnk sekvenca koja djeluje kao izolator kromatina i njena upotreba u ekspresiji proteina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8133699B2 (hr) |
| EP (1) | EP1675956B1 (hr) |
| JP (1) | JP4745972B2 (hr) |
| AT (1) | ATE484591T1 (hr) |
| AU (1) | AU2004284243B2 (hr) |
| CA (1) | CA2541523A1 (hr) |
| CY (1) | CY1110868T1 (hr) |
| DE (1) | DE602004029598D1 (hr) |
| DK (1) | DK1675956T3 (hr) |
| ES (1) | ES2354160T3 (hr) |
| HR (1) | HRP20100560T1 (hr) |
| IL (1) | IL175021A (hr) |
| NO (1) | NO338767B1 (hr) |
| PL (1) | PL1675956T3 (hr) |
| PT (1) | PT1675956E (hr) |
| SI (1) | SI1675956T1 (hr) |
| WO (1) | WO2005040384A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4307079B2 (ja) | 2001-01-26 | 2009-08-05 | セレキス エスアー | マトリックス付着領域およびその使用方法 |
| AU2004219917B2 (en) | 2003-03-11 | 2008-01-31 | Merck Serono Sa | Expression vectors comprising the mCMV IE2 promoter |
| PL1622939T3 (pl) * | 2003-05-13 | 2012-08-31 | Merck Serono Sa | Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania |
| EP2287302B1 (en) | 2003-10-24 | 2012-12-26 | Selexis S.A. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences |
| ES2285543T3 (es) | 2003-11-05 | 2007-11-16 | Ares Trading S.A. | Procedimiento para la purificacion de la proteina de union a il-18. |
| US7553665B2 (en) | 2004-03-01 | 2009-06-30 | Ares Trading S.A. | Process for the cultivation of mammalian cells producing IL-18BP in serum-free cell culture medium |
| CA2569795C (en) | 2004-06-29 | 2013-08-13 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| JP5199073B2 (ja) | 2005-06-03 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | 組換えｉｌ−１８結合タンパク質の生産 |
| CA2610804C (en) * | 2005-06-10 | 2013-11-19 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| EP1760092A1 (en) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System for screening cells for high expression of a protein of interest |
| FR2919616A1 (fr) * | 2007-08-02 | 2009-02-06 | Ecole Norm Superieure Lyon | Polynucleotides insulateurs derives de l'element d4z4 et leurs utilisations en transgenese |
| WO2012139195A1 (en) | 2011-04-13 | 2012-10-18 | National Research Council Of Canada | EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNα2 |
| DK2794886T3 (en) * | 2011-12-21 | 2017-02-27 | Danisco Us Inc | IMPROVEMENT OF FUNGAL Gene EXPRESSION USING ISOLATOR DNA SEQUENCES |
| KR101923632B1 (ko) | 2012-07-31 | 2018-12-03 | 이스케이프 테라퓨틱스, 인코퍼레이티드 | Hla g-변형된 세포 및 방법 |
| KR101591823B1 (ko) | 2013-12-27 | 2016-02-04 | 재단법인 목암생명공학연구소 | 증가된 유전자 발현능을 갖는 발현벡터 |
| WO2017075395A1 (en) * | 2015-10-28 | 2017-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Tumor-specific adenovirus vectors and therapeutic uses |
| JP6909212B2 (ja) | 2015-10-28 | 2021-07-28 | サンガモ セラピューティクス， インコーポレイテッド | 肝臓特異的コンストラクト、第ｖｉｉｉ因子発現カセット、およびその使用の方法 |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| CN106754817B (zh) * | 2016-11-03 | 2021-02-05 | 山西省生物研究院有限公司 | 一种重组自分泌运动因子的表达方法 |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| EP4065712A4 (en) * | 2019-11-29 | 2024-05-29 | Paros Bio, Inc. | GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US6432700B1 (en) * | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| US6194152B1 (en) * | 1997-08-20 | 2001-02-27 | Dendreon Corporation | Prostate tumor polynucleotide compositions and methods of detection thereof |
| US6395549B1 (en) * | 1998-10-22 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors |
| CA2377929A1 (en) | 1999-06-30 | 2001-01-11 | Adam C. Bell | Dna binding protein and sequence as insulators having specific enhancer blocking activity for regulation of gene expression |
| AU2004219917B2 (en) * | 2003-03-11 | 2008-01-31 | Merck Serono Sa | Expression vectors comprising the mCMV IE2 promoter |
| PL1622939T3 (pl) * | 2003-05-13 | 2012-08-31 | Merck Serono Sa | Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania |
| ES2285543T3 (es) * | 2003-11-05 | 2007-11-16 | Ares Trading S.A. | Procedimiento para la purificacion de la proteina de union a il-18. |
| US7553665B2 (en) | 2004-03-01 | 2009-06-30 | Ares Trading S.A. | Process for the cultivation of mammalian cells producing IL-18BP in serum-free cell culture medium |
| CA2569795C (en) | 2004-06-29 | 2013-08-13 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| JP5199073B2 (ja) | 2005-06-03 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | 組換えｉｌ−１８結合タンパク質の生産 |
| CA2610804C (en) | 2005-06-10 | 2013-11-19 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
-
2004
- 2004-10-20 CA CA002541523A patent/CA2541523A1/en not_active Abandoned
- 2004-10-20 AU AU2004284243A patent/AU2004284243B2/en not_active Expired
- 2004-10-20 EP EP04791263A patent/EP1675956B1/en not_active Expired - Lifetime
- 2004-10-20 WO PCT/EP2004/052591 patent/WO2005040384A1/en active Application Filing
- 2004-10-20 US US10/576,509 patent/US8133699B2/en active Active
- 2004-10-20 DE DE602004029598T patent/DE602004029598D1/de not_active Expired - Lifetime
- 2004-10-20 PL PL04791263T patent/PL1675956T3/pl unknown
- 2004-10-20 ES ES04791263T patent/ES2354160T3/es not_active Expired - Lifetime
- 2004-10-20 DK DK04791263.9T patent/DK1675956T3/da active
- 2004-10-20 SI SI200431541T patent/SI1675956T1/sl unknown
- 2004-10-20 PT PT04791263T patent/PT1675956E/pt unknown
- 2004-10-20 JP JP2006536087A patent/JP4745972B2/ja not_active Expired - Lifetime
- 2004-10-20 AT AT04791263T patent/ATE484591T1/de active
-
2006
- 2006-04-20 IL IL175021A patent/IL175021A/en active IP Right Grant
- 2006-05-22 NO NO20062315A patent/NO338767B1/no unknown
-
2010
- 2010-10-14 HR HR20100560T patent/HRP20100560T1/hr unknown
- 2010-10-29 CY CY20101100982T patent/CY1110868T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1675956T3 (pl) | 2011-06-30 |
| ATE484591T1 (de) | 2010-10-15 |
| ES2354160T3 (es) | 2011-03-10 |
| SI1675956T1 (sl) | 2010-12-31 |
| AU2004284243A1 (en) | 2005-05-06 |
| NO20062315L (no) | 2006-07-18 |
| IL175021A (en) | 2011-07-31 |
| US8133699B2 (en) | 2012-03-13 |
| PT1675956E (pt) | 2010-11-04 |
| WO2005040384A1 (en) | 2005-05-06 |
| EP1675956B1 (en) | 2010-10-13 |
| NO338767B1 (no) | 2016-10-17 |
| IL175021A0 (en) | 2006-08-20 |
| JP4745972B2 (ja) | 2011-08-10 |
| US20070134761A1 (en) | 2007-06-14 |
| CY1110868T1 (el) | 2015-06-10 |
| AU2004284243B2 (en) | 2010-11-04 |
| DE602004029598D1 (de) | 2010-11-25 |
| CA2541523A1 (en) | 2005-05-06 |
| EP1675956A1 (en) | 2006-07-05 |
| JP2007508833A (ja) | 2007-04-12 |
| DK1675956T3 (da) | 2010-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100560T1 (hr) | Minimalna dnk sekvenca koja djeluje kao izolator kromatina i njena upotreba u ekspresiji proteina | |
| CA2516157A1 (en) | Expression vectors comprising the mcmv ie2 promoter | |
| Suematsu et al. | IgG1 plasmacytosis in interleukin 6 transgenic mice. | |
| ES2356620T3 (es) | Reducción de la inmunogenicidad de las proteínas de fusión. | |
| ES515800A0 (es) | "metodo para construir una secuencia de adn". | |
| Reff | High-level production of recombinant immunoglobulins in mammalian cells | |
| EA199900483A1 (ru) | δ-ЭНДОТОКСИНЫ ШИРОКОГО СПЕКТРА ДЕЙСТВИЯ | |
| ES2564227T3 (es) | Elemento de ADN que tiene actividad de aumento de expresión de un gen exógeno | |
| Platis et al. | High yield expression, refolding, and characterization of recombinant interferon α2/α8 hybrids in Escherichia coli | |
| CN103865947A (zh) | 一种包含弱化的sv40启动子/二氢叶酸还原酶表达元件的真核表达载体及其构建方法 | |
| US20090111146A1 (en) | Antibody Drug | |
| US9085627B2 (en) | Expression system with SAR element from IFNα2 | |
| EP1957660B1 (en) | Materials and methods to increase peptide chain expression | |
| KR20210081989A (ko) | 동물세포 발현벡터 | |
| Li et al. | A bifunctional vector suitable for both site-directed mutagenesis and recombinant expression of interferon-τ in Escherichia coli | |
| JP2017070224A (ja) | 遺伝子発現用カセット及びその産生物 | |
| Eccles | Development of expression systems for eukaryotic proteins in E. coli and mammalian cells | |
| Class et al. | Patent application title: Expression System With Sar Element From IFNalpha2 Inventors: Yves Durocher (Montreal, CA) Assignees: NATIONAL RESEARCH COUNCIL OF CANADA | |
| CA2459013A1 (en) | Proteins having effects of controlling cell migration and cell death | |
| CN110607326A (zh) | 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用 | |
| Ross et al. | M5S 1A8 CANADA |